The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Michael H. Carrel CEO | NASDAQ (NMS) Exchange | 04963C209 CUSIP |
| US Country | 1,300 Employees | - Last Dividend | - Last Split | 5 Aug 2005 IPO Date |
AtriCure, Inc. is a medical device company that specializes in the development, manufacturing, and sales of surgical tools designed for the ablation of cardiac tissue, the exclusion of the left atrial appendage, and the temporary blocking of pain through peripheral nerve ablation. The company operates on a global scale, with a significant presence in the United States, Europe, the Asia-Pacific region, and other international markets. Since its incorporation in 2000, AtriCure has established its headquarters in Mason, Ohio, and has expanded its market reach through a combination of direct sales staff and independent distributors. AtriCure's mission is centered around innovating cardiac care, particularly focusing on solutions to address atrial fibrillation and related conditions.
AtriCure boasts a diverse portfolio of products and services designed to support cardiac surgery and pain management. The company’s offerings include: